A ntigenic peptides with affinity sufficient to activate T cell response, so-called agonists, are not the only peptides encountered by the T cell receptor (TCR) on the surface of antigen-presenting cells (APCs). Usually, TCR faces a myriad of different peptides bound to MHC molecules, which are detained in the interface between the APC and the T cell, most of which have undetectable (i.e., null) affinity for the TCR. The rules and mechanisms that govern the trafficking of MHC͞peptide complexes on the membrane of the APC, which are involved in the regulation of the T cell response, are not well understood. Some recent evidence suggests that APCs can autonomously organize the distribution of MHC͞peptide complexes on their surface. Colocalization of a diverse set of these complexes within lipid rafts may improve the presentation of less frequent peptides to T cells, whereas the accumulation of class II MHC molecules bound with a few abundant peptides in tetraspan microdomains may be a favorable target for particular subpopulations of T cells (1, 2). On the other hand, the qualitative sorting of MHC͞ peptide complexes on APCs is also actively driven by TCRs during the onset of T cell activation (3). Initially, it was reported that on activation, CD4 ϩ T cells selectively cluster agonist class II MHC͞peptide complexes, but in subsequent studies it was found that null class II MHC͞peptide complexes with weak or no affinity for TCRs are also present within the cell-cell contact site (3, 4). It was also shown that TCR engagement by MHC molecules loaded with so-called antagonist peptide may inhibit T cell response (5). It is not clear whether this effect is because of the direct interference with TCR binding to agonist MHC͞ peptide complexes (6-8) or because of the interference with the formation of functional MHC͞peptide clusters at the T cell-APC interface, as observed for other receptor͞ligand interactions (9). To investigate the latter possibility we analyzed the effect of exogenously added antagonist peptide on the redistribution of agonist and null class II MHC͞peptide complexes in the interface area of dendritic cells (DCs) interacting with naive ) were generated at the Medical College of Georgia (Augusta) (10). All mice were housed under specific pathogen-free conditions in the animal care facility at the Medical College of Georgia. DNA encoding CD3 (kindly provided by Makio Iwashima, Medical College of Georgia) was cloned into pECFP-N1 and pEYFP-N1 vectors. DNA fragments encoding CD3-CFP or CD3-YFP were recloned into the LZRS-pBMN-Z retroviral vector.
A ntigenic peptides with affinity sufficient to activate T cell response, so-called agonists, are not the only peptides encountered by the T cell receptor (TCR) on the surface of antigen-presenting cells (APCs). Usually, TCR faces a myriad of different peptides bound to MHC molecules, which are detained in the interface between the APC and the T cell, most of which have undetectable (i.e., null) affinity for the TCR. The rules and mechanisms that govern the trafficking of MHC͞peptide complexes on the membrane of the APC, which are involved in the regulation of the T cell response, are not well understood. Some recent evidence suggests that APCs can autonomously organize the distribution of MHC͞peptide complexes on their surface. Colocalization of a diverse set of these complexes within lipid rafts may improve the presentation of less frequent peptides to T cells, whereas the accumulation of class II MHC molecules bound with a few abundant peptides in tetraspan microdomains may be a favorable target for particular subpopulations of T cells (1, 2) . On the other hand, the qualitative sorting of MHC͞ peptide complexes on APCs is also actively driven by TCRs during the onset of T cell activation (3) . Initially, it was reported that on activation, CD4 ϩ T cells selectively cluster agonist class II MHC͞peptide complexes, but in subsequent studies it was found that null class II MHC͞peptide complexes with weak or no affinity for TCRs are also present within the cell-cell contact site (3, 4) . It was also shown that TCR engagement by MHC molecules loaded with so-called antagonist peptide may inhibit T cell response (5). It is not clear whether this effect is because of the direct interference with TCR binding to agonist MHC͞ peptide complexes (6) (7) (8) or because of the interference with the formation of functional MHC͞peptide clusters at the T cell-APC interface, as observed for other receptor͞ligand interactions (9) . To investigate the latter possibility we analyzed the effect of exogenously added antagonist peptide on the redistribution of agonist and null class II MHC͞peptide complexes in the interface area of dendritic cells (DCs) interacting with naive Tg   ) were generated at the Medical College of Georgia (Augusta) (10) . All mice were housed under specific pathogen-free conditions in the animal care facility at the Medical College of Georgia. DNA encoding CD3 (kindly provided by Makio Iwashima, Medical College of Georgia) was cloned into pECFP-N1 and pEYFP-N1 vectors. DNA fragments encoding CD3-CFP or CD3-YFP were recloned into the LZRS-pBMN-Z retroviral vector. was 1.5-2.5 ϫ 10 7 viral particles per ml. Viral supernatants were snap frozen in liquid nitrogen and stored at Ϫ70°C.
Isolation of Naive T Cells. Lymph node cells of the TCR Tg mouse were used as a source of naive CD4 ϩ T cells. Cells, resuspended at the concentration of 1 ϫ 10 7 per ml, were incubated for 30 min at 4°C with anti-CD4 magnetic beads (CD4 MicroBeads, Miltenyi Biotec, Auburn, CA). TCR Tg CD4 ϩ T cells were isolated by positive selection with the autoMACS sorter (Miltenyi Biotec). The purity of cells was 95-99% as tested by flow cytometry.
Generation of Activated CD4 ؉ T Cells. Lymph node cells from a TCR Tg mouse (2 ϫ 10 6 per ml) were cultured in the presence of 50 M agonist PCCVA peptide. After 48 h, cells were spun on the Lymphocyte Separation Medium (Cellgro, Herndon, VA) and blasts were further expanded in the presence of IL-2. Activated TCR Tg CD4 ϩ T cells were used for microscopy experiments on days 6-8 after isolation. The purity of cells was Ͼ95% as tested by flow cytometry.
Transduction of Activated T Cells. At day 3 of activation, TCR Tg CD4 ϩ T cells were transferred into 6-well plates and resuspended in 1 ml per well of IL-2-supplemented medium at a concentration 2 ϫ 10 6 cells per ml. Viral supernatants (300 l) and Polybrene (8 g͞ml, Sigma) were added to each well. Transduction was enhanced by the centrifugation of six-well plates enclosed in CO 2 -supplemented zip-lock bags at 1,000 ϫ g for 1 h at ambient temperature (28-32°C). Sixteen hours after transduction, Polybrene and viral supernatants were washed off and the cells were resuspended in medium with IL-2. On day 5, transduced activated TCR Tg CD4 ϩ T cells were analyzed by flow cytometry and used for microscopy experiments on days 6-8 after isolation. mice were incubated in medium supplemented with granulocyte͞macrophage colonystimulating factor (GM-CSF)-containing supernatant (15%) and IL-4 (50 units͞ml, PeproTech, Rocky Hill, NJ) and plated onto 10 mm Petri dishes at Ϸ3 ϫ 10 6 cells per ml. On day 2 cells were transferred into six-well plates and resuspended in 1 ml per well of cytokine-supplemented medium at a concentration of 3-4 ϫ 10 6 cells per ml. Viral supernatants and Polybrene (8 g͞ml) were added to each well. Transduction was enhanced by centrifugation of six-well plates enclosed in CO 2 -supplemented zip-lock bags at 1,000 ϫ g for 1 h at ambient temperature. The transduction procedure was repeated on days 3 and 4. Eight to 10 hours after transduction, Polybrene and viral supernatants were washed off and the cells were resuspended in medium containing GM-CSF and IL-4 (14) . On day 8, transduced DCs were analyzed by flow cytometry to determine the efficiency of transduction, and they were used for microscopy experiments on days 8-10 after isolation.
Flow Cytometry Analysis. The reagents used for flow cytometry analyses were as follows: anti-CD11c-PE (PharMingen), anti-A b Ep-biotin (YAe, self-prepared), anti-A b -biotin (Y3P, selfprepared), and streptavidin-CyChrome (PharMingen). Staining was done on ice in BSS buffer containing 2% FBS and 0.1% NaN 3 . All fluorescence-activated cell sorter (FACS) analyses were performed by using a FACSCalibur flow cytometer (Becton Dickinson) and CELLQUEST software (Becton Dickinson).
Detection of Ca 2؉ Influx. Calcium influx was detected by using fluo-3 AM (Molecular Probes). Fluo-3 was loaded into cells as described (15) with minor modifications. Cells (1 ϫ 10 7 per ml) were incubated in PBS with 2 M fluo-3 AM and 0.02% pluronic acid F-127 (Molecular Probes) for 20 min at room temperature. Next, the cells were diluted to a final concentration of 2 ϫ 10 6 per ml with PBS containing 1% FCS, and incubated for an additional 40 min in a 37.5 Ϯ 0.1°C water bath (16) . Cells were then washed twice with PBS and maintained in RPMI medium 1640 (Cellgro), buffered with 25 mM Hepes and supplemented with 10% FBS͞2 mM L-glutamine (Cellgro). An increase in the intensity of fluorescence of at least 50% above the resting level was considered significant for calcium influx.
Microscopy. Pictures were taken with an Axiovert S100 2TV microscope (Zeiss) equipped with the DeltaVision system (Applied Precision, Issaquah, WA) by using a CFP͞YFP set of narrow-band filters (Chroma Technology, Brattleboro, VT). An oil-immersion ϫ100͞1.40 numerical aperture objective warmed to 37°C by the Objective Heater System (Bioptechs, Butler, PA) was used. All images were deconvoluted by using a constrainediterative mode of deconvolution, applying 10 iterations. Threedimensional images were reconstructed from Z-stacks of 2D/ two-wavelength images. For image analysis LSM 510 software (Zeiss) was used. Live T cells and DCs were resuspended in Hepes-buffered medium, mixed together, and placed in a temperature-controlled chamber (Bioptechs) for immediate imaging (for calcium influx experiments with fluo-3). Alternatively, to increase the number of conjugates, T cells and DCs were mixed and spun at 50 ϫ g for 5 min and incubated at 37°C for 15 min. Next, pellets were gently resuspended and cells were placed in a temperature-controlled chamber. After 15 min, T cell-DC conjugates were subjected to imaging.
Analysis of Cell-Cell Contacts. The area of contact in the T cell-DC conjugate, showing clear cell-cell contact, was defined based on the differential interference contrast (DIC) images. Accumulation of A b ͞peptide complexes was considered as clustering when the ratio of fluorescence intensity at the interface over the side of the cell (Figs. 6 and 7, which are published as supporting information on the PNAS web site, www.pnas.org) was greater than 1.5 (50% increase in fluorescence intensity).
For 3D visualization of intercellular contacts only those complexes were taken into consideration whose contact areas (n ϭ 39)* (n ϭ 36)* (n ϭ 37)* A b Ep expulsion 0% -0% 0% 2.1 Ϯ 3.6% (n ϭ 38) (n ϭ 39)* (n ϭ 36)* (n ϭ 37)* n ϭ number of analyzed T cell-DC conjugates. *Conjugates with A b PCCVA clustering.
†, P ϭ 0.001; ‡, P ϭ 0.024; §, P ϭ 0.025 (t test, 95% confidence interval of the difference, significant when P Ͻ 0.05).
were flat enough to be contained in a rectangular volume for a facing projection. Conjugates in which the plane of the interface was not orthogonal to the Z-stacks were disregarded during analysis. Exclusion of a particular complex was defined by at least a 50% decrease in the fluorescence intensity in comparison with the intensity of complexes in the proximity of the place of contact (Figs. 6 and 7, which are published as supporting information on the PNAS web site).
In Ep-CFP (or YFP) complexes as described above, and irradiated at day 8 with a dose of 3,000 rad. These DCs (10 4 
For in vitro antagonism assay, transduced DCs were pulsed for 3 h with different concentrations of either antagonist (PCC50E) or null (PCC50Q) peptides (10) . DCs were then cocultured with TCR Tg CD4 ϩ T cells as described above. For microscopy experiments transduced DCs were pulsed for 3 h with 50 M antagonist peptide PCC50E as indicated. As shown in Fig. 1A , substantial proportion of DCs transduced simultaneously with both types of retroviruses expressed both complexes on the cell surface at comparable levels. Importantly, transduction did not result in a significant increase of the expression level of peptide͞MHC II complexes on BM-derived DCs (Fig. 1B) . When transduced separately with one type of vector, only DCs expressing the covalent A b PCCVA complexes, but not DCs expressing covalent A b Ep complexes, were able to activate transgenic CD4 ϩ T cells, demonstrating that engineered complexes retained their original specificity (Fig. 1C) . The uniform distribution of the covalent A b ͞peptide complexes on the surface of DCs indicates that the spontaneous clustering of these complexes (2) does not occur (data not shown).
Results

Covalent
To test whether class II MHC molecules covalently bound with agonist peptides can be clustered in the T cell-APC interface as observed during formation of the immunological synapse (4, 18), DCs expressing A b PCCVA complexes tagged with CFP were mixed either with naive or with effector TCR Tg CD4 ϩ T cells loaded with the calcium influx indicator fluo-3 or transfected with CD3-YFP, respectively (Fig. 2) . The transduced T cells expressed a physiological level of TCR, probably because remaining endogenous CD3 chains limit expression of TCR͞CD3 complexes. The monitoring of fluctuations in fluo-3 fluorescence as well as clustering of TCR͞CD3 complexes allowed us to ensure that the observed T cell-DC contacts were functional, i.e., led to the T cell activation. The TCR͞CD3 complex tagged with YFP also allowed us to follow the spatial relationship between formation of TCR and A b PCCVA clusters. As shown in Fig. 2 (see also Tg ͞CD3 complexes were formed at the T cell-DC interface, which was associated with T cell activation. The clustering occurs when both naive and effector T cells become activated. We also noticed that simultaneous interaction of several naive ( Fig. 2A f and g ) or effector (Fig. 2B a and d To examine the bilateral relocation of agonist and null A b ͞ peptide complexes on the interaction with naive and effector TCR Tg CD4 ϩ T cells, DCs coexpressing both complexes were used. As shown in Fig. 3 A-C PCCVA complexes in the cellcell contact site. This phenomenon of preferential relocation of agonist complexes inward, and of null complexes outward of the DC-T cell junction, observed in the majority of contact sites (see Table 1 ), was confirmed by the 3D reconstruction of the interface of DC contacting the naive TCR Tg CD4 ϩ T cell (Fig.  3 D-F) .
In contrast to naive CD4 ϩ T cells, the above described selective reorganization of agonist and null A b ͞peptide complexes at the DC-T cell interface was not observed during the interaction of effector CD4 ϩ T cells with DCs (Fig. 4 and (Fig. 6 , which is published as supporting information on the PNAS web site). Three independent experiments were done, and a total of 88 contacts were analyzed (Table 1) . This phenomenon was also observed in the opposite experimental setup, where TCR-specific A b ͞PCCVA complex was labeled with CFP and neutral A b ͞Ep complex was labeled with YFP (data not shown; Fig. 7 , which is published as supporting information on the PNAS web site). Table 1 ). In the latter case, both types of complexes are clustered at the DC-T cell interface as indicated by the formation of ''overlaid patches'' of agonist A b PCCVA-YFP (green) and null A b Ep-CFP (blue) complexes (compare Figs. 3 and 4) . These results suggest that to become activated, naive CD4 ϩ T cells, unlike effector T cells, tend to exclude irrelevant class II MHC͞peptide complexes from the site of TCR-mediated interaction with DCs. Fig. 5 B-G clearly demonstrates that the inhibition of the T cell activation by antagonist PCC50E peptide is associated with poor expulsion of the null A b Ep complexes from the DC-T cell interface (compare with Fig. 3 ). The presentation of the null PCC50Q peptide had no such effect (Table  1) . We conclude that interference with selective relocation of agonist and null MHC͞peptide complexes on the surface of DCs contributes to the inhibitory effect of antagonist peptides on the response of naive CD4 ϩ T cells to agonist ligands.
Discussion
We have shown that DCs coexpressing recombinant complexes of class II MHC molecules covalently bound to agonist and null (Table 1) . Table 1) . Expulsion of a particular complex was defined by at least a 50% decrease in the intensity of fluorescence in comparison with the intensity in the proximity of the place of contact. T cell-DC contacts (103 in total) were analyzed in three independent experiments.
peptides represent a suitable experimental model for the study of the reorganization of TCR-specific and TCR-nonspecific MHC͞peptide complexes, which occur at the intercellular contact site during interaction with naive or effector T cells. In agreement with previous experiments, by using noncovalent TCR ligands, we observed that contact with DCs expressing covalent agonist A b ͞peptide complexes resulted in TCR͞CD3 clustering and detectable calcium flux in both types of T cells, which was accompanied by simultaneous clustering of the MHC͞ peptide complexes at the T cell-DC interface (4, 18) . We found, however, a striking difference between the behavior of null MHC͞peptide complexes at the contact site of DCs interacting with naive or effector CD4 ϩ T cells. In contrast to effector T cells, naive T cells tended to exclude the MHC molecules bound to null peptides from the contact area with DCs, suggesting that a higher local concentration of agonist ligand is required for activation of ''antigen-inexperienced'' than ''antigen-experienced'' T cells. This observation is intriguing in view of the recent report that not only agonist, but also null MHC͞peptide complexes, accumulate in immune synapses and contribute to T cell recognition (3). Our findings imply that the enhancing role of nonagonist MHC͞peptide may be restricted to effector T cells only, whereas the presence of such complexes in the ''synapse'' formed by naive T cell and DC would have an opposite effect. At present, one can only speculate about the mechanism enabling naive T cells to selectively expel the nonagonist complexes from the immune synapse, and therefore more experiments will be needed to propose the explanation for this phenomenon. As far as the ''T cell side'' is concerned, it was reported (20) that activation-induced membrane changes increasing TCR avidity may contribute to the increased sensitivity of activated T cells to antigen. One could imagine that the lack of activation-induced membrane changes in naive T cells could be compensated by local increase in antigen concentration on DCs brought about by expulsion of null MHC͞peptide complexes from the contact area. However, irrespective of the mechanism involved, we made another interesting observation with regard to the possible mechanism contributing to the inhibitory effect of antagonist peptides on the antigen-specific response of naive CD4 ϩ T cells. Several mechanisms have been postulated to account for the inhibition of T cell activation by antagonist peptides. Most of them are concerned with the effects on TCR-mediated signaling pathways in T cells (21) (22) (23) (24) , and largely ignored the possible influence of antagonist peptides on the relocation of MHC͞ peptide complexes in T cell-DC interface. It was therefore very interesting to find that exposure to antagonist peptides obstructs exclusion of the null MHC͞peptide complexes from the immunological synapse formed by DCs interacting with naive CD4 ϩ T cells. In this context, it is worth mentioning that according to a recent study (25) TCR-mediated signaling in naive T cells peaks before the mature synapse is formed, suggesting another, asyet-unrecognized, role of TCR͞MHC͞peptide clusters in activation of naive T cells. One favored possibility is that cluster formation is important for TCR down-modulation and endocytosis. If this is the case, our results may indicate that antagonist peptides act by causing the retention of irrelevant MHC͞peptide complexes in the synapse and prevent sufficient contact between TCR and agonist MHC͞peptide ligands required for TCR internalization. The fact that antagonist peptides were shown to inhibit TCR endocytosis (26) is consistent with this idea. Thus, the reorganization of agonist and nonagonist MHC͞peptide complexes on the surface of DCs during the activation of naive CD4 ϩ T cells may be an important part of the mechanism that controls the initiation of the adaptive immune response.
